La asociación de los niveles de nitrotirosina con la enfermedad cardiovascular y la modulación por terapia con estatinas
Video Experimental Relacionado
Updated: Jul 9, 2026
07:53
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
Mehdi H Shishehbor1, Ronnier J Aviles, Marie-Luise Brennan
1Department of Cell Biology, and the Center for Cardiovascular Diagnostics and Prevention, the Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
JAMA
|April 4, 2003
Resumen
Los niveles elevados de nitrotirosina indican un mayor riesgo de enfermedad arterial coronaria (EAC). La terapia con estatinas reduce efectivamente estos niveles, lo que sugiere un papel para los oxidantes derivados del óxido nítrico en la inflamación y la aterosclerosis.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- La bioquímica es la bioquímica.
- Investigación de la inflamación Investigación de la inflamación.
Sus antecedentes:
- Los oxidantes derivados del óxido nítrico pueden vincular la inflamación con el desarrollo de la aterosclerosis.
- La nitrotirosina, un marcador de la modificación oxidante, se encuentra en lesiones ateroscleróticas y LDL.
Objetivo del estudio:
- Investigar la asociación entre los niveles sistémicos de nitrotirosina y la prevalencia de la enfermedad arterial coronaria (CAD).
- Para determinar si el tratamiento con estatinas influye en los niveles de nitrotirosina.
Principales métodos:
- Un estudio de casos y controles comparó los niveles de nitrotirosina en 100 pacientes con CAD y 108 controles.
- Un estudio intervencionista trató a 35 pacientes con hipercolesterolemia con atorvastatina (10 mg/día) durante 12 semanas.
Principales resultados:
- Los niveles de nitrotirosina fueron significativamente más altos en pacientes con CAD (P<.001).
- Los cuartiles de nitrotirosina más altos se asociaron con un aumento de las probabilidades de CAD, incluso después del ajuste multivariado (OR, 4.4; P<.001).
- El tratamiento con estatinas redujo los niveles de nitrotirosina en un 25% (P<.02), independientemente de los cambios en las lipoproteínas o la PCR.
Conclusiones:
- Los niveles sistémicos de nitrotirosina están asociados con la presencia de CAD.
- La terapia con estatinas puede modular los niveles de nitrotirosina, lo que sugiere un papel para los oxidantes derivados del óxido nítrico en la patogénesis de la CAD.
- Los hallazgos implican el potencial de la nitrotirosina en la evaluación del riesgo de aterosclerosis y el monitoreo de los efectos antiinflamatorios de las estatinas.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.